Stockreport

Final Study Completed for Cingulate’s Lead Asset CTx-1301

Cingulate Inc.  (CING) 
PDF No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NAS [Read more]